bioAffinity Technologies (NASDAQ:BIAF) Issues Quarterly Earnings Results, Beats Estimates By $1.46 EPS

bioAffinity Technologies (NASDAQ:BIAF) released its earnings results on Friday. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($2.10) by $1.46, FiscalAI reports. bioAffinity Technologies had a negative return on equity of 285.75% and a negative net margin of 280.53%.The firm had revenue of $1.51 million for the quarter, compared to the consensus estimate of $1.70 million.

bioAffinity Technologies Trading Down 3.7%

BIAF stock opened at $0.51 on Friday. The company has a market cap of $2.42 million, a price-to-earnings ratio of -0.04 and a beta of -1.05. The company has a quick ratio of 1.34, a current ratio of 1.36 and a debt-to-equity ratio of 0.15. The business has a fifty day simple moving average of $0.93 and a 200-day simple moving average of $1.64. bioAffinity Technologies has a 52 week low of $0.51 and a 52 week high of $13.50.

Wall Street Analyst Weigh In

Several analysts have commented on BIAF shares. Weiss Ratings restated a “sell (e+)” rating on shares of bioAffinity Technologies in a report on Monday, July 20th. Wall Street Zen lowered shares of bioAffinity Technologies from a “hold” rating to a “sell” rating in a report on Sunday, August 2nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. J. Safra Sarasin Holding AG purchased a new stake in bioAffinity Technologies during the first quarter valued at about $164,000. Geode Capital Management LLC acquired a new position in shares of bioAffinity Technologies in the 4th quarter valued at about $36,000. Finally, Scientech Research LLC acquired a new position in shares of bioAffinity Technologies in the 3rd quarter valued at about $49,000. Institutional investors and hedge funds own 1.64% of the company’s stock.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.